Maralixibat
Phase 3Recruiting 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
Conditions
Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
Trial Timeline
Oct 14, 2024 → Feb 1, 2027
NCT ID
NCT06553768About Maralixibat
Maralixibat is a phase 3 stage product being developed by Mirum Pharmaceuticals for Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06553768. Target conditions include Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC).
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04530994 | Pre-clinical | Completed |
| NCT07389031 | Phase 2 | Recruiting |
| NCT06553768 | Phase 3 | Recruiting |
| NCT04729751 | Phase 2 | Completed |
| NCT04524390 | Phase 2 | Completed |
| NCT04168385 | Phase 2 | Completed |
| NCT04185363 | Phase 3 | Completed |
| NCT03905330 | Phase 3 | Completed |
Competing Products
3 competing products in Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| A4250 + CRC (A3384) + Questran + Placebo | Ipsen | Phase 1 | 30 |
| 3 mg [14C]-A4250 capsule | Ipsen | Phase 1 | 30 |
| Maralixibat | Mirum Pharmaceuticals | Phase 2 | 49 |